{"doc_id": "33542047", "type of study": "Therapy", "title": "", "abstract": "Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial.\nTo evaluate whether the addition of colchicine to standard treatment for COVID-19 results in better outcomes.\nWe present the results of a randomised, double-blinded, placebo-controlled clinical trial of colchicine for the treatment of moderate to severe COVID-19, with 75 patients allocated 1:1 from 11 April to 30 August 2020.\nColchicine regimen was 0.5\u2009mg thrice daily for 5\u2009days, then 0.5\u2009mg twice daily for 5\u2009days.\nThe primary endpoints were the need for supplemental oxygen, time of hospitalisation, need for admission and length of stay in intensive care unit and death rate.\nSeventy-two patients (36 for placebo and 36 for colchicine) completed the study.\nMedian (and IQR) time of need for supplemental oxygen was 4.0 (2.0-6.0)\u2009days for the colchicine group and 6.5 (4.0-9.0)\u2009days for the placebo group (p<0.001).\nMedian (IQR) time of hospitalisation was 7.0 (5.0-9.0)\u2009days for the colchicine group and 9.0 (7.0-12.0)\u2009days for the placebo group (p=0.003).\nAt day 2, 67% versus 86% of patients maintained the need for supplemental oxygen, while at day 7, the values were 9% versus 42%, in the colchicine and the placebo groups, respectively (log rank; p=0.001).\nTwo patients died, both in placebo group.\nDiarrhoea was more frequent in the colchicine group (p=0.26).\nColchicine reduced the length of both, supplemental oxygen therapy and hospitalisation.\nThe drug was safe and well tolerated.\nOnce death was an uncommon event, it is not possible to ensure that colchicine reduced mortality of COVID-19.\nTRIAL REGISTRATION NUMBER : RBR-8jyhxh.\n\u00a9 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY.\nPublished by BMJ.\n", "Evidence Map": {"Enrollment": [{"term": "moderate to severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 64}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 81}, {"term": "moderate to severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 127, "end": 154}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Beneficial effects of colchicine for moderate to severe COVID-19 : a randomised , double-blinded , placebo-controlled clinical trial .", "Evidence Elements": {"Participant": [{"term": "moderate to severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 64}], "Intervention": [{"term": "colchicine", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 32}], "Outcome": [{"term": "Beneficial effects", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 18}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVE", "Text": "To evaluate whether the addition of colchicine to standard treatment for COVID-19 results in better outcomes .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 81}], "Intervention": [{"term": "addition of colchicine to standard treatment", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 68}], "Outcome": [{"term": "outcomes", "negation": "affirmed", "UMLS": {}, "start": 100, "end": 108}], "Observation": [{"term": "better", "negation": "affirmed", "UMLS": {}, "start": 93, "end": 99}], "Count": []}, "Evidence Propositions": []}, {"Section": "DESIGN", "Text": "We present the results of a randomised , double-blinded , placebo-controlled clinical trial of colchicine for the treatment of moderate to severe COVID-19 , with 75 patients allocated 1:1 from 11 April to 30 August 2020 .", "Evidence Elements": {"Participant": [{"term": "moderate to severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 127, "end": 154}], "Intervention": [{"term": "colchicine", "negation": "affirmed", "UMLS": {}, "start": 95, "end": 105}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "DESIGN", "Text": "Colchicine regimen was 0.5 mg thrice daily for 5 days , then 0.5 mg twice daily for 5 days .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Colchicine regimen", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 18}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "DESIGN", "Text": "The primary endpoints were the need for supplemental oxygen , time of hospitalisation , need for admission and length of stay in intensive care unit and death rate .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "need for supplemental oxygen", "negation": "affirmed", "UMLS": {}, "start": 31, "end": 59}, {"term": "time of hospitalisation", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 85}, {"term": "need for admission", "negation": "affirmed", "UMLS": {}, "start": 88, "end": 106}, {"term": "length of stay in intensive care unit", "negation": "affirmed", "UMLS": {}, "start": 111, "end": 148}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Seventy-two patients ( 36 for placebo and 36 for colchicine ) completed the study .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 37}, {"term": "colchicine", "negation": "affirmed", "UMLS": {}, "start": 49, "end": 59}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Median ( and IQR ) time of need for supplemental oxygen was 4.0 ( 2.0-6.0 ) days for the colchicine group and 6.5 ( 4.0-9.0 ) days for the placebo group ( p < 0.001 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "colchicine", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 99}], "Outcome": [{"term": "Median ( and IQR ) time of need for supplemental oxygen", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 55}], "Observation": [{"term": "4.0 ( 2.0-6.0 ) days", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 80}, {"term": "6.5 ( 4.0-9.0 )", "negation": "affirmed", "UMLS": {}, "start": 110, "end": 125}], "Count": []}, "Evidence Propositions": [{"Intervention": "colchicine", "Observation": "4.0 ( 2.0-6.0 ) days", "Outcome": "Median ( and IQR ) time of need for supplemental oxygen", "Count": ""}]}, {"Section": "RESULTS", "Text": "Median ( IQR ) time of hospitalisation was 7.0 ( 5.0-9.0 ) days for the colchicine group and 9.0 ( 7.0-12.0 ) days for the placebo group ( p=0.003 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "colchicine", "negation": "affirmed", "UMLS": {}, "start": 72, "end": 82}], "Outcome": [{"term": "Median ( IQR ) time of hospitalisation", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 38}], "Observation": [{"term": "7.0 ( 5.0-9.0 ) days", "negation": "affirmed", "UMLS": {}, "start": 43, "end": 63}, {"term": "9.0 ( 7.0-12.0 )", "negation": "affirmed", "UMLS": {}, "start": 93, "end": 109}], "Count": []}, "Evidence Propositions": [{"Intervention": "colchicine", "Observation": "7.0 ( 5.0-9.0 ) days", "Outcome": "Median ( IQR ) time of hospitalisation", "Count": ""}]}, {"Section": "RESULTS", "Text": "At day 2 , 67 % versus 86 % of patients maintained the need for supplemental oxygen , while at day 7 , the values were 9 % versus 42 % , in the colchicine and the placebo groups , respectively ( log rank ; p = 0.001 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "colchicine", "negation": "affirmed", "UMLS": {}, "start": 144, "end": 154}], "Outcome": [{"term": "need for supplemental oxygen", "negation": "affirmed", "UMLS": {}, "start": 55, "end": 83}, {"term": "values", "negation": "affirmed", "UMLS": {}, "start": 107, "end": 113}], "Observation": [{"term": "9 %", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 122}, {"term": "42 %", "negation": "affirmed", "UMLS": {}, "start": 130, "end": 134}], "Count": [{"term": "67 %", "negation": "affirmed", "UMLS": {}, "start": 11, "end": 15}, {"term": "86 % of patients", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 39}]}, "Evidence Propositions": [{"Intervention": "colchicine", "Observation": "9 %", "Outcome": "values", "Count": ""}, {"Intervention": "colchicine", "Observation": "42 %", "Outcome": "values", "Count": ""}]}, {"Section": "RESULTS", "Text": "Two patients died , both in placebo group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 35}], "Outcome": [{"term": "died", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 17}], "Observation": [], "Count": [{"term": "Two patients", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 12}]}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Diarrhoea was more frequent in the colchicine group ( p = 0.26 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "colchicine", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 45}], "Outcome": [{"term": "Diarrhoea", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 9}], "Observation": [{"term": "more frequent", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 27}], "Count": []}, "Evidence Propositions": [{"Intervention": ["colchicine"], "Observation": "more frequent", "Outcome": "Diarrhoea", "Count": ""}]}, {"Section": "CONCLUSION", "Text": "Colchicine reduced the length of both , supplemental oxygen therapy and hospitalisation .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Colchicine", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 10}], "Outcome": [{"term": "length of both , supplemental oxygen therapy and", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 71}], "Observation": [{"term": "reduced", "negation": "affirmed", "UMLS": {}, "start": 11, "end": 18}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSION", "Text": "The drug was safe and well tolerated .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [{"term": "safe", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 17}, {"term": "well tolerated", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 36}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSION", "Text": "Once death was an uncommon event , it is not possible to ensure that colchicine reduced mortality of COVID-19 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "colchicine", "negation": "negated", "UMLS": {}, "start": 69, "end": 79}], "Outcome": [{"term": "mortality", "negation": "negated", "UMLS": {}, "start": 88, "end": 97}], "Observation": [{"term": "reduced", "negation": "negated", "UMLS": {}, "start": 80, "end": 87}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "TRIAL REGISTRATION NUMBER : RBR-8jyhxh .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "RBR-8jyhxh", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 38}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "\u00a9 Author (s ) ( or their employer (s ) ) 2021 . Re-use permitted under CC BY .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by BMJ .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}